Lycopene destabilizes preformed Aβ fibrils: Mechanistic insights from all-atom molecular dynamics simulation

The therapeutic strategy employing destabilization of the preformed Aβ fibril by various natural compounds, as studied by experimental and computational methods, has been reported significant in curing Alzheimer's disease (AD). However, lycopene (a carotenoid), from terpenes family, needs investigation for its destabilization potential of Aβ fibril. The highest antioxidant potential and ability to cross blood brain barrier makes lycopene a preferred choice as drug lead for treating AD. The current study focuses on investigating the destabilization potential and underpinning mechanism of lycopene on different polymorphic forms of Aβ fibril via Molecular Dynamics (MD) simulation. The key findings highlight binding of lycopene to the outer surface of the chain F of the fibril (2NAO). Herein G9, K16 and V18 residues were found to be involved in van der Waals with the methyl groups of the lycopene. Additionally, Y10 and F20 residues were observed to interact via π-π interactions with CC bonds of the lycopene. The surface mediated binding of lycopene to the fibril is attributed to the large size and structural rigidity of lycopene along with the bulky size of 2NAO and narrow space of fibrillar cavity. The destabilization of the fibril is evident by breakage of inherent H-bonds and hydrophobic interactions in the presence of one lycopene molecule. The lesser β-sheet content explains disorganization of the fibril and bars the higher order aggregation curbing neurotoxicity of the fibril. The higher concentration of the lycopene is not found to be linearly correlated with the extent of destabilization of the fibril. Lycopene is also observed to destabilize the other polymorphic form of Aβ fibril (2BEG), by accessing the fibrillar cavity and lowering the β-sheet content. The destabilization observed by lycopene on two major polymorphs of Aβ fibril explains its potency towards developing an effective therapeutic approach in treating AD.

[1]  Lin F. Yang,et al.  Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019 , 2022, The Lancet. Public health.

[2]  A. K. Dasmahapatra,et al.  Destabilization of Aβ fibrils by omega-3 polyunsaturated fatty acids: a molecular dynamics study , 2021, Journal of biomolecular structure & dynamics.

[3]  N. Xu,et al.  Lycopene-Loaded Microemulsion Regulates Neurogenesis in Rats with Aβ-Induced Alzheimer's Disease Rats Based on the Wnt/β-catenin Pathway , 2021, Neural plasticity.

[4]  R. Joshi,et al.  Destabilization potential of beta sheet breaker peptides on Abeta fibril structure: an insight from molecular dynamics simulation study , 2021, RSC advances.

[5]  A. K. Dasmahapatra,et al.  Destabilization of the Alzheimer's amyloid-β protofibrils by THC: A molecular dynamics simulation study. , 2021, Journal of molecular graphics & modelling.

[6]  Bill R. Miller,et al.  Biflavonoid-Induced Disruption of Hydrogen Bonds Leads to Amyloid-β Disaggregation , 2021, International journal of molecular sciences.

[7]  Guanghong Wei,et al.  Serotonin and Melatonin Show Different Modes of Action on Aβ42 Protofibril Destabilization. , 2021, ACS chemical neuroscience.

[8]  A. K. Dasmahapatra,et al.  Destabilization potential of phenolics on Aβ fibrils: mechanistic insights from molecular dynamics simulation. , 2020, Physical chemistry chemical physics : PCCP.

[9]  T. Bera,et al.  Therapeutic and medicinal uses of lycopene: a systematic review , 2020 .

[10]  S. Basu,et al.  Identifying the key residues instrumental in imparting stability to amyloid beta protofibrils – a comparative study using MD simulations of 17–42 residues , 2020, Journal of biomolecular structure & dynamics.

[11]  M. Kim,et al.  Editorial: Natural Products-Based Drugs: Potential Therapeutics Against Alzheimer’s Disease and Other Neurological Disorders , 2019, Front. Pharmacol..

[12]  Chhandak Basu,et al.  Therapeutic and Medicinal Uses of Terpenes , 2019, Medicinal Plants.

[13]  S. Kang,et al.  Polyphenolic Biflavonoids Inhibit Amyloid-Beta Fibrillation and Disaggregate Preformed Amyloid-Beta Fibrils , 2019, Biomolecules & therapeutics.

[14]  A. K. Dasmahapatra,et al.  Caffeine destabilizes preformed Aβ protofilaments: insights from all atom molecular dynamics simulations. , 2019, Physical chemistry chemical physics : PCCP.

[15]  Deepti Goyal,et al.  Insights into the inhibitory mechanism of a resveratrol and clioquinol hybrid against Aβ42 aggregation and protofibril destabilization: A molecular dynamics simulation study , 2019, Journal of biomolecular structure & dynamics.

[16]  M. J. Ramalho,et al.  Natural Compounds for Alzheimer’s Disease Therapy: A Systematic Review of Preclinical and Clinical Studies , 2019, International journal of molecular sciences.

[17]  Sagar S. Barale,et al.  Molecular Insights into Destabilization of Alzheimer’s Aβ Protofibril by Arginine Containing Short Peptides: A Molecular Modeling Approach , 2019, ACS Omega.

[18]  H. Ågren,et al.  Destabilization of amyloid fibrils on interaction with MoS2-based nanomaterials , 2019, RSC advances.

[19]  Guanghong Wei,et al.  Norepinephrine Inhibits Alzheimer's Amyloid-β Peptide Aggregation and Destabilizes Amyloid-β Protofibrils: A Molecular Dynamics Simulation Study. , 2019, ACS chemical neuroscience.

[20]  S. Hägg,et al.  Circulating antioxidants and Alzheimer disease prevention: a Mendelian randomization study , 2018, The American journal of clinical nutrition.

[21]  J. Morley,et al.  Alzheimer Disease. , 2018, Clinics in geriatric medicine.

[22]  V. Basile,et al.  Curcumin derivatives and Aβ-fibrillar aggregates: An interactions' study for diagnostic/therapeutic purposes in neurodegenerative diseases. , 2018, Bioorganic & medicinal chemistry.

[23]  Guanghong Wei,et al.  Dihydrochalcone molecules destabilize Alzheimer's amyloid-β protofibrils through binding to the protofibril cavity. , 2018, Physical chemistry chemical physics : PCCP.

[24]  M. Menziani,et al.  Computational Insight into the Effect of Natural Compounds on the Destabilization of Preformed Amyloid-β(1–40) Fibrils , 2018, Molecules.

[25]  Sung Bae Lee,et al.  Recent Advances in Studies on the Therapeutic Potential of Dietary Carotenoids in Neurodegenerative Diseases , 2018, Oxidative medicine and cellular longevity.

[26]  Zhen Gao,et al.  Lycopene mitigates β-amyloid induced inflammatory response and inhibits NF-κB signaling at the choroid plexus in early stages of Alzheimer's disease rats. , 2018, The Journal of nutritional biochemistry.

[27]  Bhupesh Goyal,et al.  Molecular insights into Aβ42 protofibril destabilization with a fluorinated compound D744: A molecular dynamics simulation study , 2017, Journal of molecular recognition : JMR.

[28]  Dev Mehta,et al.  Why do trials for Alzheimer’s disease drugs keep failing? A discontinued drug perspective for 2010-2015 , 2017, Expert opinion on investigational drugs.

[29]  Sandip Paul,et al.  The role of caffeine as an inhibitor in the aggregation of amyloid forming peptides: a unified molecular dynamics simulation and experimental study , 2016 .

[30]  Peter Güntert,et al.  Atomic-resolution structure of a disease-relevant Aβ(1–42) amyloid fibril , 2016, Proceedings of the National Academy of Sciences.

[31]  D. Greenwood,et al.  Blood concentrations of carotenoids and retinol and lung cancer risk: an update of the WCRF–AICR systematic review of published prospective studies , 2016, Cancer medicine.

[32]  Ashok Sharma,et al.  Molecular insight into amyloid oligomer destabilizing mechanism of flavonoid derivative 2-(4′ benzyloxyphenyl)-3-hydroxy-chromen-4-one through docking and molecular dynamics simulations , 2016, Journal of biomolecular structure & dynamics.

[33]  I. Petyaev.  Lycopene Deficiency in Ageing and Cardiovascular Disease , 2016, Oxidative medicine and cellular longevity.

[34]  P. Hof,et al.  Tau Protein Hyperphosphorylation and Aggregation in Alzheimer’s Disease and Other Tauopathies, and Possible Neuroprotective Strategies , 2016, Biomolecules.

[35]  Huanhuan Xing,et al.  Lycopene attenuates Aβ1–42 secretion and its toxicity in human cell and Caenorhabditis elegans models of Alzheimer disease , 2015, Neuroscience Letters.

[36]  K. P. Kepp,et al.  The Dependence of Amyloid-β Dynamics on Protein Force Fields and Water Models. , 2015, Chemphyschem : a European journal of chemical physics and physical chemistry.

[37]  K. Chopra,et al.  Lycopene abrogates Aβ(1-42)-mediated neuroinflammatory cascade in an experimental model of Alzheimer's disease. , 2015, The Journal of nutritional biochemistry.

[38]  Dongqing Wei,et al.  Destabilization of Alzheimer's Aβ42 Protofibrils with a Novel Drug Candidate wgx-50 by Molecular Dynamics Simulations. , 2015, The journal of physical chemistry. B.

[39]  Shaoyi Jiang,et al.  Brazilin inhibits amyloid β-protein fibrillogenesis, remodels amyloid fibrils and reduces amyloid cytotoxicity , 2015, Scientific Reports.

[40]  Simone Brogi,et al.  Disease‐Modifying Anti‐Alzheimer's Drugs: Inhibitors of Human Cholinesterases Interfering with β‐Amyloid Aggregation , 2014, CNS neuroscience & therapeutics.

[41]  Liang Liu,et al.  Catechins and Procyanidins of Ginkgo biloba Show Potent Activities towards the Inhibition of β-Amyloid Peptide Aggregation and Destabilization of Preformed Fibrils , 2014, Molecules.

[42]  J. Min,et al.  Serum Lycopene, Lutein and Zeaxanthin, and the Risk of Alzheimer's Disease Mortality in Older Adults , 2013, Dementia and Geriatric Cognitive Disorders.

[43]  P. Galan,et al.  Carotenoid-rich dietary patterns during midlife and subsequent cognitive function , 2013, British Journal of Nutrition.

[44]  J. Bieschke.  Natural Compounds May Open New Routes to Treatment of Amyloid Diseases , 2013, Neurotherapeutics.

[45]  S. Chong,et al.  Structural heterogeneity in familial Alzheimer's disease mutants of amyloid-beta peptides. , 2013, Molecular bioSystems.

[46]  V. Barone,et al.  The effects of ferulic acid on β-amyloid fibrillar structures investigated through experimental and computational techniques. , 2013, Biochimica et biophysica acta.

[47]  R. Mayeux,et al.  Epidemiology of Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[48]  L. Ferrucci,et al.  Serum carotenoids and pulmonary function in older community-dwelling women , 2012, The journal of nutrition, health & aging.

[49]  Pramod C. Nair,et al.  An Automated Force Field Topology Builder (ATB) and Repository: Version 1.0. , 2011, Journal of chemical theory and computation.

[50]  A. Middelberg,et al.  Molecular insight into conformational transition of amyloid β-peptide 42 inhibited by (-)-epigallocatechin-3-gallate probed by molecular simulations. , 2011, The journal of physical chemistry. B.

[51]  K. Cousins,et al.  Computer review of ChemDraw Ultra 12.0. , 2011, Journal of the American Chemical Society.

[52]  W. V. van Gunsteren,et al.  Validation of the GROMOS 54A7 Force Field with Respect to β-Peptide Folding. , 2011, Journal of chemical theory and computation.

[53]  R. Sandhir,et al.  Protective Effect of Lycopene on Oxidative Stress and Cognitive Decline in Rotenone Induced Model of Parkinson’s Disease , 2011, Neurochemical Research.

[54]  Simon W. Ginzinger,et al.  SHIFTX2: significantly improved protein chemical shift prediction , 2011, Journal of biomolecular NMR.

[55]  Kyle L. Morris,et al.  Hydrophobic, aromatic, and electrostatic interactions play a central role in amyloid fibril formation and stability. , 2011, Biochemistry.

[56]  Justin A. Lemkul,et al.  Destabilizing Alzheimer's Abeta(42) protofibrils with morin: mechanistic insights from molecular dynamics simulations. , 2010, Biochemistry.

[57]  J. Monti,et al.  The Polyphenol Piceid Destabilizes Preformed Amyloid Fibrils and Oligomers In Vitro: Hypothesis on Possible Molecular Mechanisms , 2009, Neurochemical Research.

[58]  H. Ernst,et al.  The chemistry of novel xanthophyll carotenoids. , 2008, The American journal of cardiology.

[59]  Nicolas L. Fawzi,et al.  Protofibril assemblies of the arctic, Dutch, and Flemish mutants of the Alzheimer's Abeta1-40 peptide. , 2008, Biophysical journal.

[60]  R. Nussinov,et al.  Modeling the Alzheimer Abeta17-42 fibril architecture: tight intermolecular sheet-sheet association and intramolecular hydrated cavities. , 2007, Biophysical journal.

[61]  M. Parrinello,et al.  Canonical sampling through velocity rescaling. , 2007, The Journal of chemical physics.

[62]  J. Straub,et al.  Dynamics of Asp23-Lys28 salt-bridge formation in Abeta10-35 monomers. , 2006, Journal of the American Chemical Society.

[63]  Qi Dai,et al.  Fruit and vegetable juices and Alzheimer's disease: the Kame Project. , 2006, The American journal of medicine.

[64]  H. Scheraga,et al.  The role of hydrophobic interactions in initiation and propagation of protein folding , 2006, Proceedings of the National Academy of Sciences.

[65]  Gerrit Groenhof,et al.  GROMACS: Fast, flexible, and free , 2005, J. Comput. Chem..

[66]  R. Riek,et al.  3D structure of Alzheimer's amyloid-β(1–42) fibrils , 2005 .

[67]  K. Ono,et al.  Ferulic acid destabilizes preformed β-amyloid fibrils in vitro , 2005 .

[68]  R. Rossi,et al.  Passionflower fruit-a "new" source of lycopene? , 2005, Journal of medicinal food.

[69]  Pawel Sikorski,et al.  Molecular basis for amyloid fibril formation and stability. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[70]  Chris Oostenbrink,et al.  A biomolecular force field based on the free enthalpy of hydration and solvation: The GROMOS force‐field parameter sets 53A5 and 53A6 , 2004, J. Comput. Chem..

[71]  G. Mishra,et al.  Tomato consumption and plasma lycopene concentration in people aged 65 y and over in a British national survey , 2003, European Journal of Clinical Nutrition.

[72]  Ibrahim Elmadfa,et al.  Biological Relevance of Terpenoids , 2003, Annals of Nutrition and Metabolism.

[73]  David Heber,et al.  Overview of Mechanisms of Action of Lycopene , 2002, Experimental biology and medicine.

[74]  S. Mayne,et al.  Plasma lycopene concentrations in humans are determined by lycopene intake, plasma cholesterol concentrations and selected demographic factors. , 1999, The Journal of nutrition.

[75]  Berk Hess,et al.  LINCS: A linear constraint solver for molecular simulations , 1997, J. Comput. Chem..

[76]  Ad Bax,et al.  Quantitative J correlation: a new approach for measuring homonuclear three-bond J(HNH.alpha.) coupling constants in 15N-enriched proteins , 1993 .

[77]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[78]  T. Straatsma,et al.  THE MISSING TERM IN EFFECTIVE PAIR POTENTIALS , 1987 .

[79]  S. Nosé,et al.  Constant pressure molecular dynamics for molecular systems , 1983 .

[80]  W. Kabsch,et al.  Dictionary of protein secondary structure: Pattern recognition of hydrogen‐bonded and geometrical features , 1983, Biopolymers.

[81]  L. Verlet.  Computer "Experiments" on Classical Fluids. I. Thermodynamical Properties of Lennard-Jones Molecules , 1967 .

[82]  I. Jahan,et al.  Destabilization of Alzheimer’s Aβ42 protofibrils with acyclovir, carmustine, curcumin, and tetracycline: Insights from molecular dynamics simulations , 2021, New Journal of Chemistry.

[83]  S. Przybylska.  Lycopene – a bioactive carotenoid offering multiple health benefits: a review , 2019, International Journal of Food Science & Technology.

[84]  Yan Cheng,et al.  Neuroprotective effects of lycopene pretreatment on transient global cerebral ischemia‑reperfusion in rats: The role of the Nrf2/HO‑1 signaling pathway. , 2016, Molecular medicine reports.

[85]  J. Woodside,et al.  Carotenoids and health in older people. , 2015, Maturitas.

[86]  J. Erdman,et al.  Nutritional aspects of phytoene and phytofluene, carotenoid precursors to lycopene. , 2011, Advances in nutrition.

[87]  E. Esposito,et al.  Intake of tomato-enriched diet protects from 6-hydroxydopamine-induced degeneration of rat nigral dopaminergic neurons. , 2009, Journal of neural transmission. Supplementum.

[88]  H. Bosshard,et al.  Protein stabilization by salt bridges: concepts, experimental approaches and clarification of some misunderstandings , 2004, Journal of molecular recognition : JMR.

[89]  I. AndreaLeBlanc.  The role of -amyloid peptide in alzheimer's disease , 1994 .

[90]  M. Karplus.  Contact Electron‐Spin Coupling of Nuclear Magnetic Moments , 1959 .